錢(qián)雪明博士是創(chuàng)勝集團(tuán)醫(yī)藥有限公司（下稱創(chuàng)勝集團(tuán)）的首席執(zhí)行官。創(chuàng)勝集團(tuán)是一家具備生物藥發(fā)現(xiàn)、研發(fā)、工藝開(kāi)發(fā)和生產(chǎn)全流程整合能力的臨床階段的生物制藥公司。2021年9月29日，創(chuàng)勝集團(tuán)在香港聯(lián)合交易所主板上市，股票代碼：06628。
錢(qián)雪明博士畢業(yè)于復(fù)旦大學(xué)生物物理學(xué)系 (1985 – 1990)，并分別在哥倫比亞大學(xué) (Columbia University, 1990 – 1992) 和奧爾巴尼醫(yī)學(xué)中心 (Albany Medical Center, 1995 – 1997) 獲得神經(jīng)學(xué)與生理學(xué)碩士學(xué)位和神經(jīng)學(xué)與藥理學(xué)博士學(xué)位。
錢(qián)雪明博士擁有 20 年的生物制藥行業(yè)經(jīng)驗(yàn)。在創(chuàng)立創(chuàng)勝集團(tuán)之前，錢(qián)博士于 2010-2013 年間任盛諾基醫(yī)藥集團(tuán) (Shenogen Pharma Group) 研發(fā)總裁和董事會(huì)成員。1997-2010 間任職于美國(guó)安進(jìn)公司，專注于抗體新藥的開(kāi)發(fā)。錢(qián)博士是十多個(gè)創(chuàng)新藥物專利申請(qǐng)的發(fā)明人，也是國(guó)際抗體協(xié)會(huì)會(huì)員、國(guó)際腎病協(xié)會(huì)會(huì)員、新藥創(chuàng)始人俱樂(lè)部、創(chuàng)新生物社和 BayHelix 百華協(xié)會(huì)會(huì)員，獲得了國(guó)家級(jí)高層次人才、蘇州工業(yè)園區(qū)科技領(lǐng)軍人才和蘇州市姑蘇創(chuàng)新創(chuàng)業(yè)領(lǐng)軍人才等支持。
Dr. Xueming Qian is the CEO of Transcenta Holding Limited (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics.?
Dr. Qian received his B.S. in Biophysics from Fudan University (Shanghai, China, 1985 – 1990), M.A. in Neuroscience/Physiology from Columbia University (New York, USA, 1990 – 1992) and Ph.D. in Neuroscience and Pharmacology from Albany Medical Center (New York, USA, 1995 – 1997).
Dr. Qian has over twenty years of industrial experience in biotechnology drug discovery and development. Before starting Transcenta, Dr. Qian was Senior VP and R&D Head of Shenogen Pharma Group from 2010 and 2013. Dr. Qian worked more than 12 years at Amgen as principal scientist and project team leader from 1997 and 2010. Dr. Qian is the author over ten patent applications and a member of the New Drug Founder’s Club, Bio-logics Innovation Group, BayHelix as well as several scientific organizations such as ASCO, ESMO, AACR, ASN and Antibody Society.?